Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education

Background. Inflammatory bowel disease (IBD) affects patients in their young reproductive years. Women with IBD require maintenance therapies during pregnancy and breastfeeding. However, physician management of IBD during pregnancy and breastfeeding has not been well characterized. Objective. To characterize physician perceptions and management of IBD during pregnancy and breastfeeding. Methods. A cross-sectional survey of Canadian physicians who are involved in the care of women with IBD was conducted. The survey included multiple-choice and Likert scale questions about perceptions and practice patterns regarding the management of IBD during pregnancy and breastfeeding. Results. 183 practicing physicians completed the questionnaire: 97/183 (53.0%) gastroenterologists; 75/183 (41.0%) general practitioners; and 11/183 (6.0%) other physicians. Almost half (87/183, 47.5%) of the physicians felt comfortable managing pregnant IBD patients. For specified IBD medications, proportions of physicians who indicated they would continue them during pregnancy were as follows: sulfasalazine, 47.4%; oral mesalamine, 67.0%; topical mesalamine, 70.3%; oral prednisone, 68.0%; topical prednisone, 78.0%; oral budesonide, 61.6%; topical budesonide, 75.0%; ciprofloxacin, 15.3%; metronidazole, 31.4%; azathioprine, 57.1%; methotrexate, 2.8%; infliximab, 55.6%; adalimumab, 78.1%. Similar proportions of physicians would continue these medications during breastfeeding. A higher proportion of gastroenterologists than nongastroenterologists indicated appropriate use of these IBD medications during pregnancy and breastfeeding. Conclusions. Physician management of IBD during pregnancy and breastfeeding varies widely. Relative to other physicians, responses of gastroenterologists more frequently reflected best practices pertaining to medications for control of IBD during pregnancy and breastfeeding. There is a need for further education regarding the management of IBD during pregnancy and breastfeeding.

[1]  R. Sarpong,et al.  Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02572c , 2019, Chemical science.

[2]  A. Bitton,et al.  The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. , 2016, Gastroenterology.

[3]  C. J. van der Woude,et al.  Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety , 2015, Gut.

[4]  C. J. van der Woude,et al.  The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. , 2015, Journal of Crohn's & colitis.

[5]  F. Granath,et al.  Birth Outcomes in Women with Inflammatory Bowel Disease: Effects of Disease Activity and Drug Exposure , 2014, Inflammatory bowel diseases.

[6]  L. A. Christensen,et al.  Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease. , 2014, Journal of Crohn's & colitis.

[7]  O. Nielsen,et al.  IBD medications during pregnancy and lactation , 2014, Nature Reviews Gastroenterology &Hepatology.

[8]  J. Gisbert,et al.  The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO‐EpiCom Study of 209 pregnant women , 2013, Alimentary pharmacology & therapeutics.

[9]  M. Lukáš,et al.  Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study , 2013, Scandinavian journal of gastroenterology.

[10]  J. Mclaughlin,et al.  Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. , 2013, Journal of Crohn's & colitis.

[11]  G. Lichtenstein,et al.  Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. , 2013, World journal of gastroenterology.

[12]  J. Mate,et al.  Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease , 2013, The American Journal of Gastroenterology.

[13]  D. Toomey,et al.  Family planning and inflammatory bowel disease: the patient and the practitioner. , 2013, Family practice.

[14]  U. Mahadevan,et al.  Management of inflammatory bowel disease in pregnancy , 2013, Expert review of clinical immunology.

[15]  S. Shah,et al.  Systematic Review and Meta-analysis on the Effects of Thiopurines on Birth Outcomes from Female and Male Patients with Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[16]  S. Vermeire,et al.  Management of inflammatory bowel disease in pregnancy. , 2012, Journal of Crohn's & colitis.

[17]  J. Andrews,et al.  General practitioners' knowledge of and attitudes to inflammatory bowel disease , 2012, Internal medicine journal.

[18]  Christopher F. Martin,et al.  865 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy , 2012 .

[19]  R. Fedorak,et al.  Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients , 2012, Inflammatory bowel diseases.

[20]  W. Marsden.  I and J , 2012 .

[21]  R. Eliakim,et al.  Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. , 2011, Journal of Crohn's & colitis.

[22]  K. Van Steen,et al.  Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy , 2011, Inflammatory bowel diseases.

[23]  G. Koren,et al.  Safety of infliximab use during pregnancy. , 2011, Reproductive toxicology.

[24]  G. Eslick,et al.  The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). , 2011, Journal of Crohn's & colitis.

[25]  C. Papi,et al.  Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis. , 2011, Journal of Crohn's & colitis.

[26]  S. Zeuzem,et al.  Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. , 2011, Journal of Crohn's & colitis.

[27]  R. Arsenescu,et al.  TNF-α and the Development of the Neonatal Immune System: Implications for Inhibitor Use in Pregnancy , 2011, The American Journal of Gastroenterology.

[28]  F. Granath,et al.  Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden , 2011, Inflammatory bowel diseases.

[29]  L. Peyrin-Biroulet,et al.  The use of azathioprine in Crohn’s disease during pregnancy and in the post‐operative setting: a worldwide survey of experts , 2011, Alimentary pharmacology & therapeutics.

[30]  S. Travis,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics , 2011, The American Journal of Gastroenterology.

[31]  L. Peyrin-Biroulet,et al.  Use of azathioprine during pregnancy and in the postoperative setting in Crohn?s disease: A worldwide survey of experts , 2011 .

[32]  J. Sanderson,et al.  Management of inflammatory bowel disease in pregnancy , 2010, Obstetric medicine.

[33]  J. Andrews,et al.  Pregnancy and IBD treatment: this challenging interplay from a patients' perspective. , 2010, Journal of Crohn's & colitis.

[34]  S. Ben-Horin,et al.  Adalimumab level in breast milk of a nursing mother. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  E. Kuipers,et al.  Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases , 2010, Scandinavian journal of gastroenterology.

[36]  F. Carrat,et al.  Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study , 2009, Gut.

[37]  I. Mylonas.  Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration , 2010, Archives of Gynecology and Obstetrics.

[38]  C. Wagner,et al.  Absence of Infliximab in Infants and Breast Milk From Nursing Mothers Receiving Therapy for Crohn's Disease Before and After Delivery , 2009, Journal of clinical gastroenterology.

[39]  J. Andrews,et al.  Fear and fertility in inflammatory bowel disease: A mismatch of perception and reality affects family planning decisions , 2009, Inflammatory bowel diseases.

[40]  G. Koren,et al.  The safety of quinolones--a meta-analysis of pregnancy outcomes. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[41]  Joel Z Stengel,et al.  Is infliximab safe to use while breastfeeding? , 2008, World journal of gastroenterology.

[42]  R. Caprilli,et al.  Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. , 2008, Inflammatory bowel diseases.

[43]  S. Nikfar,et al.  Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. , 2008, Reproductive toxicology.

[44]  H. Sørensen,et al.  Therapeutic Drug Use in Women With Crohn's Disease and Birth Outcomes: A Danish Nationwide Cohort Study , 2007, The American Journal of Gastroenterology.

[45]  H. Sørensen,et al.  Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study , 2006, Alimentary pharmacology & therapeutics.

[46]  S. Targan,et al.  Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[47]  D. Mishkin,et al.  Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. , 2006, Inflammatory bowel diseases.

[48]  A. Tursi.  Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[49]  J. Terdiman,et al.  Adalimumab use in pregnancy , 2005, Gut.

[50]  W. Sandborn,et al.  Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease , 2005, Alimentary pharmacology & therapeutics.

[51]  G. Lichtenstein,et al.  Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis , 2004, The American Journal of Gastroenterology.

[52]  C. Bodian,et al.  The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients , 2004, American Journal of Gastroenterology.

[53]  C. Bodian,et al.  The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. , 2003, Gastroenterology.

[54]  G. H. Lambert,et al.  Transfer of drugs and other chemicals into human milk. , 2001, Pediatrics.

[55]  R. Hughes,et al.  The effects of methotrexate on pregnancy, fertility and lactation. , 1999, QJM : monthly journal of the Association of Physicians.

[56]  Marteau,et al.  Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules , 1998, Alimentary pharmacology & therapeutics.

[57]  G. Koren,et al.  The safety of mesalamine in human pregnancy: a prospective controlled cohort study. , 1998, Gastroenterology.

[58]  R. Alexander.  The Transfer of Drugs and Other Chemicals Into Human Milk , 1994, Pediatrics.

[59]  G. Greenberg,et al.  Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. , 1993, Gastroenterology.

[60]  S. Gabbe,et al.  Simultaneous concentrations of ciprofloxacin in breast milk and in serum in mother and breast-fed infant. , 1992, Clinical pharmacy.

[61]  B. Korelitz,et al.  Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. , 1981, Gastroenterology.